SSTR5 Inhibitors
1 drugsAbout SSTR5
Somatostatin receptor 5 (SSTR5) is a G protein-coupled receptor that binds the somatostatin hormone, influencing cell signaling. As one of five subtypes, SSTR5 exhibits distinct tissue distribution and affinity for somatostatin analogs.
SSTR5 is a therapeutic target of interest, though no genetic evidence currently links it to specific diseases. Further research is needed to fully understand its role in disease pathogenesis.
SSTR5 is targeted by one FDA-approved drug, SIGNIFOR, a small molecule. RECORDATI RARE is the only company with an approved SSTR5-targeting drug.
Top SSTR5 Drugs
RECORDATI RARE is the only company with an approved drug targeting SSTR5.
Low competition suggests an opportunity for new entrants, but also highlights potential challenges.
SSTR5 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SSTR5, using small molecule modality.
The lack of diverse modalities indicates an opportunity to develop novel biologics.
SSTR5 Clinical Trials 53 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SSTR5. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 9 | 1 | 0 | 90% |
| Phase 2 | 29 | 15 | 11 | 3 | 58% |
| Phase 3 | 8 | 8 | 0 | 0 | 100% |
| Phase 4 | 6 | 4 | 1 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
SSTR5 Drug Approval Timeline (2012 - 2012)
The first and only drug, SIGNIFOR, was approved in 2012.
The stagnant approval timeline indicates a potentially saturated market or challenges in drug development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 32 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SSTR5. A trial counts if an approved drug acting on SSTR5 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.